The weight-loss world is on the brink of a major shake-up. Pharmaceutical companies in India will get the green light this ...

In India, China and several other nations, Novo Nordisk is on the verge of losing patent protection for its blockbuster ...

Generic versions of semaglutide — the active ingredient in Ozempic and Wegovy — are set to begin rolling out in India, Canada ...

As geopolitical uncertainties persist, the possibility of a Canadian-made version of one of the most popular drugs in the ...

Broad generic availability of semaglutide is not expected until the early 2030s, which means most Americans will stay on branded Ozempic and Wegovy for years to come. Some patients may eye Canadian ...

Compounding pharmacies are illegally selling GLP-1 drugs, and the FDA is determined to shut that pathway down.

The generic versions of semaglutide are expected to be at least 50% cheaper— ₹5,000 for a weekly dose—than Ozempic in India .

Cheaper access to semaglutide generics must be matched by strong regulation, education and clinical discipline ...

Patent protections on semaglutide, developed by Novo Nordisk, will lapse on March 20, opening the door for domestic ...

Generic Ozempic is set to emerge in major markets from India and Brazil to China and Canada this year, reshaping the sector in those countries.

With the patent on Semaglutide expiring, Indian pharma companies including Dr Reddy’s, Natco, Sun Pharma, and Zydus are launching generic versions of Ozempic and similar drugs, expected to reduce ...

From a diabetes drug to a global weight-loss phenomenon, semaglutide has reshaped modern medicine. As patents expire, cheaper ...